Jose A Gómez-Puerta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1522283/publications.pdf

Version: 2024-02-01

127 papers 4,478 citations

94433 37 h-index 110387 64 g-index

137 all docs

137 docs citations

times ranked

137

3992 citing authors

#	Article	IF	CITATIONS
1	Controversies in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2022, 28, e651-e658.	0.9	1
2	High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study. Diagnostics, 2022, 12, 182.	2.6	3
3	Rheumatoid arthritis patients "al nostro cuore― European Journal of Internal Medicine, 2022, 96, 46-48.	2.2	1
4	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 2022, 81, 695-709.	0.9	130
5	Interstitial lung disease and rheumatoid arthritis. Handbook of Systemic Autoimmune Diseases, 2022, , 21-40.	0.1	O
6	The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis. JCI Insight, 2022, 7, .	5.0	11
7	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. European Journal of Internal Medicine, 2022, 99, 19-21.	2.2	4
8	OA01â€fSafety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	1.9	0
9	Bilateral striopallidal calcinosis secondary to systemic lupus erythematosus. Radiology Case Reports, 2022, 17, 2257-2261.	0.6	O
10	Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. Rheumatology, 2021, 60, 667-674.	1.9	8
11	Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis. Clinical Rheumatology, 2021, 40, 1853-1859.	2.2	12
12	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. Journal of Autoimmunity, 2021, 117, 102580.	6.5	23
13	Design of an algorithm for the diagnostic approach of patients with joint pain. Clinical Rheumatology, 2021, 40, 1581-1591.	2.2	3
14	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
15	Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 2665-2672.	2.2	1
16	Expanding diagnostic approach in patients with osteonecrosis. Arthritis Research and Therapy, 2021, 23, 150.	3.5	0
17	Diagnosis and treatment of articular manifestations of systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 90-100.	0.1	2
18	Transferrina y ceruloplasmina en orina de pacientes con lupus eritematoso sistémico. ¿Son útiles para diferenciar pacientes con nefritis lúpica?. ReumatologÃa ClÃnica, 2020, 16, 17-23.	0.5	14

#	Article	IF	Citations
19	Antinuclear antibodies mitotic patterns and their clinical associations. Annals of the Rheumatic Diseases, 2020, 79, e63-e63.	0.9	3
20	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. Rheumatology, 2020, 59, 1574-1580.	1.9	47
21	Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?. Journal of Rheumatology, 2020, 47, 652-657.	2.0	9
22	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology, 2020, 59, e165-e168.	1.9	0
23	Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses. RMD Open, 2020, 6, e001355.	3.8	5
24	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097813.	2.7	8
25	Poliautoinmunidad en sÃndrome de Sjögren. Revista Colombiana De ReumatologÃa, 2020, 27, 58-66.	0.1	2
26	Coexistence of antiphospholipid syndrome and cryoglobulinemia in a patient with rheumatoid arthritis. Clinical Rheumatology, 2020, 39, 2833-2835.	2.2	0
27	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1
28	A comparative study on clinical and serological characteristics between patients with rhupus and those with systemic lupus erythematosus and rheumatoid arthritis. Lupus, 2020, 29, 1216-1226.	1.6	12
29	Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Annals of the Rheumatic Diseases, 2020, 79, 587-594.	0.9	52
30	Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Seminars in Arthritis and Rheumatism, 2019, 49, 396-404.	3.4	50
31	Overrepresentation of Elderly Subjects in a Populationâ€Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarteâ€GarcÃa et al. Arthritis and Rheumatology, 2019, 71, 1768-1769.	5.6	1
32	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. Journal of Rheumatology, 2019, 46, 1299-1308.	2.0	21
33	THU0683â€COVERAGE, PREDICTORS OF VACCINATION AND FREQUENCY OF SEVERE INFECTIONS DUE TO STREPTOCOCCUS PNEUMONIAE IN A COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WITHIN AN EIGHTEEN-YEAR PERIOD. , 2019, , .		1
34	AB0403â€PREDICTORS OF PERSISTENCE OF BIOLOGIC DRUG STEP-DOWN STRATEGIES IN INFLAMMATORY ARTHRITIS: A LONGITUDINAL STUDY IN CLINICAL PRACTICE WITH A LONG FOLLOW-UP. , 2019, , .		0
35	FRIO591â€RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES FROM TWO REFERRAL CENTRES. , 2019, , .		0
36	AB0511â€A COMPARATIVE STUDY ON CLINICAL AND SEROLOGICAL CHARACTERISTICS BETWEEN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	ЛТН	0

#	Article	IF	CITATIONS
37	Anti C1q antibodies. A promising biomarker for cocaine-levamisole induced vasculitis. ReumatologÃa ClÃnica (English Edition), 2019, 15, e66-e67.	0.3	0
38	HMGB1 ⁺ microparticles present in urine are hallmarks of nephritis in patients with systemic lupus erythematosus. European Journal of Immunology, 2019, 49, 323-335.	2.9	26
39	Anti C1q antibodies. A promising biomarker for cocaine-levamisole induced vasculitis. ReumatologÃa ClÃnica, 2019, 15, e66-e67.	0.5	1
40	Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients. Lupus, 2018, 27, 637-646.	1.6	23
41	Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations. Medicine (United States), 2018, 97, e11727.	1.0	14
42	The Spectrum of Rheumatic Diseases. Handbook of Systemic Autoimmune Diseases, 2018, 15, 1-13.	0.1	4
43	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 I Diseases. 2018, 77, 1549-1557.</i>	0.784314 rg	BT/Overlock
44	History, Classification, and Subsets of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, , 1-16.	0.1	3
45	Antiphospholipid Syndrome Associated With Malignancies. Handbook of Systemic Autoimmune Diseases, 2017, 12, 181-191.	0.1	0
46	Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1823-1831.	5.6	70
47	Enfermedad relacionada con IgG4: revisión concisa de la literatura. ReumatologÃa ClÃnica, 2017, 13, 160-166.	0.5	46
48	Papel de la vÃa de señalización del TWEAK/Fn14 en la nefritis lúpica y otros escenarios clÃnicos. Nefrologia, 2017, 37, 118-125.	0.4	5
49	Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies. Antibodies, 2016, 5, 18.	2.5	12
50	Infiltrating CD16+ Are Associated with a Reduction in Peripheral CD14+CD16++ Monocytes and Severe Forms of Lupus Nephritis. Autoimmune Diseases, 2016, 2016, 1-7.	0.6	32
51	Retraso diagnóstico y terapéutico de la artritis reumatoide y su relación con dispositivos asistenciales en Catalunya. Estudio AUDIT. ReumatologÃa ClÃnica, 2016, 12, 146-150.	0.5	13
52	Correlación entre la actividad clÃnica por DAS-28 y ecografÃa en pacientes con artritis reumatoide. Revista Colombiana De ReumatologÃa, 2016, 23, 159-169.	0.1	0
53	Organ Damage and Quality of Life in Antiphospholipid Syndrome. Current Rheumatology Reports, 2016, 18, 7.	4.7	9
54	What impact do race and ethnicity have on lupus mortality?. International Journal of Clinical Rheumatology, 2015, 10, 223-226.	0.3	3

#	Article	IF	CITATIONS
55	Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End tage Renal Disease Due to Lupus Nephritis. Arthritis Care and Research, 2015, 67, 1453-1462.	3.4	45
56	Racial/Ethnic Variation in Allâ€Cause Mortality Among United States Medicaid Recipients With Systemic Lupus Erythematosus: A Hispanic and Asian Paradox. Arthritis and Rheumatology, 2015, 67, 752-760.	5.6	108
57	Is There Subclinical Synovitis in Patients with Palindromic Rheumatism in the Intercritical Period? A Clinical and Ultrasonographic Study According to Anticitrullinated Protein Antibody Status. Journal of Rheumatology, 2014, 41, 1650-1655.	2.0	16
58	Prolonged Remission in SLE Revisited: An Old Wine in a New Bottle. Journal of Rheumatology, 2014, 41, 1728-1731.	2.0	3
59	Laryngeal Assessment by Videolaryngostroboscopy in Patients With Rheumatoid Arthritis. ReumatologÃa ClÃnica (English Edition), 2014, 10, 32-36.	0.3	5
60	Diagnosis and classification of the antiphospholipid syndrome. Journal of Autoimmunity, 2014, 48-49, 20-25.	6.5	238
61	Valoración larÃngea mediante videolaringoestroboscopia en pacientes con artritis reumatoide. ReumatologÃa ClAnica, 2014, 10, 32-36.	0.5	6
62	The association between silica exposure and development of ANCA-associated vasculitis: Systematic review and meta-analysis. Autoimmunity Reviews, 2013, 12, 1129-1135.	5.8	135
63	Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. Journal of the American Academy of Dermatology, 2013, 69, 19-24.	1.2	36
64	Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunologic Research, 2013, 56, 287-292.	2.9	43
65	Relapsing Catastrophic Antiphospholipid Syndrome Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. Seminars in Arthritis and Rheumatism, 2013, 42, 417-423.	3.4	34
66	Catastrophic Antiphospholipid Syndrome. Clinics in Laboratory Medicine, 2013, 33, 391-400.	1.4	26
67	Are there additional options for the treatment of refractory obstetric antiphospholipid syndrome?. Lupus, 2013, 22, 754-755.	1.6	5
68	High Prevalence of Prothrombotic Abnormalities in Multifocal Osteonecrosis. Medicine (United) Tj ETQq0 0 0 rg	;BT /Overlo	ck 10 Tf 50 2
69	Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. Current Topics in Medicinal Chemistry, 2013, 13, 760-773.	2.1	34
70	Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and –negative rheumatoid arthritis patients. Arthritis Research and Therapy, 2013, 15, R182.	3.5	34
71	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. Journal of Clinical & Cellular Immunology, 2013, 04, 179.	1.5	5
72	Palindromic Rheumatism with Positive Anticitrullinated Peptide/Protein Antibodies Is Not Synonymous with Rheumatoid Arthritis. A Longterm Followup Study. Journal of Rheumatology, 2012, 39, 1929-1933.	2.0	31

#	Article	IF	CITATIONS
73	The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology. Clinical Reviews in Allergy and Immunology, 2012, 43, 256-264.	6.5	64
74	B-cell depleting agents for ANCA vasculitides: A new therapeutic approach. Autoimmunity Reviews, 2012, 11, 646-652.	5.8	34
75	Lung Sarcoidosis Induced by TNF Antagonists in Rheumatoid Arthritis: A Case Presentation and a Literature Review. Archivos De Bronconeumologia, 2011, 47, 208-212.	0.8	19
76	The Use of Chimeric Vimentin Citrullinated Peptides for the Diagnosis of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2011, 54, 7486-7492.	6.4	19
77	Effects of Smoking on Disease Activity and Radiographic Progression in Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2536-2539.	2.0	38
78	Sarcoidosis pulmonar inducida por antagonistas del factor de necrosis tumoral en la artritis reumatoide: presentaci \tilde{A}^3 n de un caso y revisi \tilde{A}^3 n de la literatura m \tilde{A} ©dica. Archivos De Bronconeumologia, 2011, 47, 208-212.	0.8	38
79	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. Autoimmunity Reviews, 2011, 10, 679-684.	5.8	58
80	Antibodies against \hat{l}^2 -fibrin synthetic peptides: A study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients. European Journal of Medicinal Chemistry, 2011, 46, 1095-1102.	5.5	6
81	Spleen tyrosine kinase inhibitors—novel therapies for RA?. Nature Reviews Rheumatology, 2011, 7, 134-136.	8.0	8
82	Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists? Rheumatology, 2011, 50, 1523-1525.	1.9	23
83	Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases. Pharmacological Reviews, 2011, 63, 127-156.	16.0	95
84	Skeletal Involvement in Antiphospholipid Syndrome. Current Rheumatology Reviews, 2010, 6, 25-31.	0.8	3
85	Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease. Chest, 2009, 136, 1101-1111.	0.8	92
86	Proliferative lupus nephritis in a patient with systemic lupus erythematosus and longstanding secondary amyloid nephropathy. Clinical Rheumatology, 2009, 28, 95-97.	2.2	5
87	Macroscopic features of knee synovitis in early untreated BehÃSet disease and psoriatic arthritis. Clinical Rheumatology, 2009, 28, 1053-1057.	2.2	12
88	Pregnancy and Catastrophic Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2009, 36, 85-90.	6.5	25
89	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the "CAPS Registryâ€. Journal of Autoimmunity, 2009, 32, 240-245.	6.5	307
90	Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Research and Therapy, 2009, 11, R135.	3.5	38

#	Article	IF	Citations
91	Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Research and Therapy, 2009, 11, R17.	3.5	51
92	Chapter 1 History, Classification, and Subsets of the Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2009, , 1-11.	0.1	3
93	Chapter 12 Antiphospholipid Syndrome Associated with Malignancies. Handbook of Systemic Autoimmune Diseases, 2009, , 149-154.	0.1	0
94	Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel Vasculitis. American Journal of Pathology, 2009, 175, 1790-1798.	3.8	69
95	Partial HELLP syndrome in pregnancy complicated by recurrent deep vein thromboses and palmar skin lesions in a patient with prothrombin gene 20210a mutation and antiphospholipid antibodies: an unusual case. Clinical Rheumatology, 2008, 27, 245-248.	2.2	7
96	Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value. Autoimmunity Reviews, 2008, 7, 606-611.	5.8	79
97	Sacral stress fracture as a cause of gluteal artery injury: An unusual complication of a common fracture. Joint Bone Spine, 2008, 75, 239-241.	1.6	2
98	llium Osteitis as the Main Manifestation of the SAPHO Syndrome: Response to Infliximab Therapy and Review of the Literature. Seminars in Arthritis and Rheumatism, 2008, 37, 299-306.	3.4	70
99	Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus, 2007, 16, 366-373.	1.6	45
100	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Annals of the Rheumatic Diseases, 2007, 66, 740-746.	0.9	89
101	Osteonecrosis múltiple. Patogénesis, caracterÃsticas clÃnicas y tratamiento. Seminarios De La Fundaciâ^šâ‰¥n Espaâ^šÂ±ola De Reumatologâ^šâ‰a, 2007, 8, 185-192.	0.1	3
102	Catastrophic Antiphospholipid Syndrome: Lessons from the "CAPS Registry" A Tribute to the Late Josep Font. Annals of the New York Academy of Sciences, 2007, 1108, 448-456.	3.8	25
103	Camptocormia as a clinical manifestation of mitochondrial myopathy. Clinical Rheumatology, 2007, 26, 1017-1019.	2.2	37
104	Recurrent congenital heart block in neonatal lupus. Clinical Rheumatology, 2007, 26, 1161-1163.	2.2	8
105	Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clinical Rheumatology, 2007, 26, 1111-1118.	2.2	47
106	Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Annals of the Rheumatic Diseases, 2006, 65, 109-111.	0.9	64
107	Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmunity Reviews, 2006, 6, 68-71.	5.8	28
108	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. Autoimmunity Reviews, 2006, 6, 72-75.	5.8	83

#	Article	lF	Citations
109	Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmunity Reviews, 2006, 6, 81-84.	5.8	30
110	Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome. Autoimmunity Reviews, 2006, 6, 85-88.	5.8	20
111	Antiphospholipid Antibodies Associated with Malignancies: Clinical and Pathological Characteristics of 120 Patients. Seminars in Arthritis and Rheumatism, 2006, 35, 322-332.	3.4	122
112	Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis and Rheumatism, 2006, 54, 2568-2576.	6.7	294
113	Anti-Chromatin (Anti-Nucleosome) Antibodies. Lupus, 2006, 15, 408-411.	1.6	25
114	Dementia associated with antiphospholipid antibodies: reply. Rheumatology, 2006, 45, 242-243.	1.9	1
115	The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Annals of the Rheumatic Diseases, 2006, 65, 81-86.	0.9	66
116	BehÃSet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. Israel Medical Association Journal, 2006, 8, 513-4.	0.1	8
117	Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. British Journal of Rheumatology, 2005, 44, 95-99.	2.3	55
118	Recurrent Pulmonary Thromboembolism in a Patient with Systemic Lupus Erythematosus and HIV-1 Infection Associated with the Presence of Antibodies to Prothrombin: A Case Report. Clinical Infectious Diseases, 2005, 41, e89-e92.	5.8	9
119	Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2005, 64, 1205-1209.	0.9	209
120	Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Annals of the Rheumatic Diseases, 2005, 64, 943-946.	0.9	74
121	Long-Term Follow-Up in 128 Patients With Primary Antiphospholipid Syndrome. Medicine (United) Tj ETQq1 1 0.	784314 rg 1.0	BT/Overlock 125
122	Accelerated nodulosis during methotrexate therapy in a patient with systemic lupus erythematosus and Jaccoud's arthropathy. British Journal of Rheumatology, 2004, 43, 1587-1588.	2.3	18
123	Coeliac disease associated with systemic sclerosis. Annals of the Rheumatic Diseases, 2004, 63, 104-105.	0.9	21
124	Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Annals of the Rheumatic Diseases, 2004, 63, 1312-1317.	0.9	161
125	Etanercept en pacientes con artritis reumatoide y escasa respuesta terapéutica a infliximab. Medicina ClÃnica, 2004, 122, 321-324.	0.6	5
126	"Catastrophic―Antiphospholipid Syndrome. Mayo Clinic Proceedings, 2003, 78, 519.	3.0	1

Jose A Gó MEZ-PUERTA

#	Article	IF	CITATIONS
127	Letter to the Editor. Lupus, 2003, 12, 866-869.	1.6	12